REGISTER
Can Combining Four Treatments Help Liver Cancer Patients Live Longer?
Dr. Abou-Alfa examines the immunological rationale behind this combination, how physicians should select and monitor patients given the overlapping toxicity risks, and what the PFS result may signal for long-term overall survival.

Ghassan K. Abou-Alfa, MD, PhD, Memorial Sloan Kettering Cancer Center, USA

The EMERALD-3 trial tested a quadruple combination in unresectable, embolization-eligible hepatocellular carcinoma: the STRIDE regimen (tremelimumab plus durvalumab), lenvatinib, and TACE. The study met its primary endpoint of progression-free survival, raising the question of whether TACE-induced tumor necrosis and antigen release can genuinely amplify the systemic activity of dual immunotherapy plus a TKI. Dr. Abou-Alfa examines the immunological rationale behind this combination, how physicians should select and monitor patients given the overlapping toxicity risks, and what the PFS result may signal for long-term overall survival.

0
0
Loading